THERAPY DOSSIER · th-590e577c8e1c

Human fetal neural stem cells (hNSCs)

Biologic · Cell therapy (human fetal neural stem cells); not a ChEMBL entity

Evidence & regulatory context

Mechanism: Cell therapy (human fetal neural stem cells); not a ChEMBL entity
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03269071 ↗PHASE1completed

Neural Stem Cell Transplantation in Multiple Sclerosis (human fetal-derived hNSCs)

Progressive Multiple Sclerosis

Enrolment: 4 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23063425 ↗2012Reported benefit

Functional assessment of the acute local and distal transplantation of human neural stem cells after spinal cord injury.

RatSpinal cord injuryContusionLong-Evans hoodedFemalen = 24 rats, 6 per group across four groupsSubdural injection at the injury site, or intrathecal injection via a separate distal laminotomyAcute, at the time of injury

Model: Moderate T10 spinal cord contusion using the Multicenter Animal Spinal Cord Injury Study impactor, 10 g weight dropped from 25 mm after laminectomy

Both local subdural and distal intrathecal transplantation of human fetal neural stem cells significantly improved Basso, Beattie and Bresnahan locomotor scores compared with media controls at p=0.034 and p=0.016 respectively, with no difference between the two routes.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…